Explanatory and pragmatic estimates of the treatment effect when deviations from allocated treatment occur
- PMID: 3201044
- DOI: 10.1002/sim.4780071111
Explanatory and pragmatic estimates of the treatment effect when deviations from allocated treatment occur
Abstract
In a randomized clinical trial comparing two treatments it can happen that certain patients receive the treatment other than that determined by random allocation. Significance testing is usually performed by 'intention to treat', that is, comparison of groups as determined by random allocation. The difference between the mean values of the outcome variable for these two groups estimates the difference in practical use between two treatment policies, corresponding to a pragmatic approach. An attenuation factor can then be used to obtain an estimate of the underlying difference in effectiveness between the two treatments, corresponding to an explanatory paradigm. Thus two distinct estimates are obtained; in many instances both are valid, but have distinct interpretations. Correspondingly, in planning sample size requirements when deviations from allocated treatment can be anticipated, the target treatment difference may be understood in either an explanatory or a pragmatic sense; for the sample size assessment method it is necessary to take this distinction into account.
Similar articles
-
A two-stage trial design for testing treatment, self-selection and treatment preference effects.Stat Med. 1989 Apr;8(4):477-85. doi: 10.1002/sim.4780080411. Stat Med. 1989. PMID: 2727471
-
An approach to the design and implementation of clinical trials of empirical antibiotic therapy in febrile and neutropenic cancer patients.Eur J Cancer. 1995 Nov;31A(12):2013-22. doi: 10.1016/0959-8049(95)00292-8. Eur J Cancer. 1995. PMID: 8562158 Review.
-
Explanatory versus pragmatic trial-based economic evaluations: application to alternative therapies for burns.Expert Rev Pharmacoecon Outcomes Res. 2010 Feb;10(1):37-48. doi: 10.1586/erp.09.75. Expert Rev Pharmacoecon Outcomes Res. 2010. PMID: 20121563 Review.
-
When was a "negative" clinical trial big enough? How many patients you needed depends on what you found.Arch Intern Med. 1985 Apr;145(4):709-12. Arch Intern Med. 1985. PMID: 3985731
-
Pragmatic versus explanatory trials.Int J Technol Assess Health Care. 1989;5(3):333-9. doi: 10.1017/s0266462300007406. Int J Technol Assess Health Care. 1989. PMID: 10318324 Review.
Cited by
-
Meta-analysis and quality of evidence in the economic evaluation of drug trials.Pharmacoeconomics. 1992 Apr;1(4):282-92. doi: 10.2165/00019053-199201040-00005. Pharmacoeconomics. 1992. PMID: 10147018
-
Basic design considerations for clinical trials in oncology.Jpn J Cancer Res. 1992 Jun;83(6):547-58. doi: 10.1111/j.1349-7006.1992.tb00124.x. Jpn J Cancer Res. 1992. PMID: 1644658 Free PMC article. Review. No abstract available.
-
Comparing Long-term Mortality After Carotid Endarterectomy vs Carotid Stenting Using a Novel Instrumental Variable Method for Risk Adjustment in Observational Time-to-Event Data.JAMA Netw Open. 2018 Sep 7;1(5):e181676. doi: 10.1001/jamanetworkopen.2018.1676. JAMA Netw Open. 2018. PMID: 30646140 Free PMC article.
-
Meta-analysis of breast cancer mortality benefit and overdiagnosis adjusted for adherence: improving information on the effects of attending screening mammography.Br J Cancer. 2016 May 24;114(11):1269-76. doi: 10.1038/bjc.2016.90. Epub 2016 Apr 28. Br J Cancer. 2016. PMID: 27124337 Free PMC article.
-
A framework for the design, conduct and interpretation of randomised controlled trials in the presence of treatment changes.Trials. 2017 Oct 25;18(1):498. doi: 10.1186/s13063-017-2240-9. Trials. 2017. PMID: 29070048 Free PMC article. Review.
MeSH terms
Substances
LinkOut - more resources
Medical